Podcasts about myelodysplastic syndromes

"We typically think of the disease progressing for our higher-risk patients because many of them already start with increased blasts or a lot of dysplasia. And they have these chromosomal variants that make them prone to evolving into acute myeloid leukemia (AML). With them, we can anticipate that they are going to progress to AML. And that's what we're trying to prevent. It's kind of like a biologic evolution and not a switch," ONS member Sara Tinsley-Vance, PhD, APRN, AOCN®, nurse practitioner and quality-of-life researcher at Moffitt Cancer Center in Tampa, FL, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about long-term myelodysplastic syndrome (MDS) considerations for oncology nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 19, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to management of long-term side effects related to myelodysplastic syndrome and its treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 415: Myelodysplastic Syndrome Treatment Considerations for Oncology Nurses Episode 411: An Overview of Myelodysplastic Syndrome for Oncology Nurses Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 220: Oncologic Emergencies 101: Febrile Neutropenia and Sepsis Clinical Journal of Oncology Nursing articles:  Exploring Experiences of Bereaved Caregivers of Older Adult Patients With Acute Myeloid Leukemia Family Caregiver Preparedness: Developing an Educational Intervention for Symptom Management Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery Oncology Nursing Forum article: An Integrative Review of Sex Differences in Quality of Life and Symptoms Among Survivors of Hematologic Malignancies ONS book: BMTCN® Certification Review Manual (second edition) ONS course: Psychosocial Dimensions of Cancer Care™  ONS Learning Libraries:  Survivorship Learning Library Hematology, Cellular Therapy, and Stem Cell Transplantation Survivorship Care Plan Huddle Card American Association of Colleges of Nursing End-of-Life Nursing Education Consortium (ELNEC) American Cancer Society: Living As a Myelodysplastic Syndrome Survivor American Society of Hematology Aplastic Anemia and MDS International Foundation: MDS Toolkit Blood Cancer United: Myelodysplastic Syndromes Family Caregiver Alliance HealthTree Foundation Inspire: MDS Support and Discussion Community Myelodysplastic Syndromes Foundation To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "When our higher-risk patients have disease-related progression, their [malignancy] can transform to AML. And we know this occurs in about one-third of our patients and is one of the most serious late effects. Even in lower-risk disease, we have this worsening marrow failure with or without increasing blast, where [patients] may have just started out with anemia, then they also develop neutropenia and thrombocytopenia. And as those counts worsen, we usually know that their disease is progressing." TS 2:47 "The golden rule is looking at the blood count but also looking at the patient and how they're doing over time. The backbone of MDS monitoring is the complete blood cell count with the differential. What you're looking for is trends over time. How many units of blood are they receiving, what threshold are you going to transfuse them at, and how many units of blood are they getting at a time? ... And then paying attention to the absolute neutrophil count for infection risk. [Another] really important piece of when you look at the differential with patients is seeing if they have any abnormal cell counts. Do they have circulating blasts? Are those monocytes going up? If you start to see blasts circulating or increasing monocytes, then their disease could be changing, even if they have low-risk disease." TS 15:58 "For lower-risk disease, we're paying more attention to their quality of life, how the patient's tolerating therapy, trying to help them stay safe over the long haul, and starting them on iron chelation if it matches that patient and they can have access to those drugs. ... For higher-risk disease, if the patient's goal is to be cured and not to progress to AML, you want to get them to transplant if that's [also] one of their goals. If they do evolve into AML, try and see what treatment matches best for them." TS 22:28 "You want to start early for patients who have febrile neutropenia—that's really important when a patient is an hour or two away from a center where they can get started on antibiotics. So, you have to think outside the box. What can we do to keep them safe? ... I know this group in Alaska that's in our advisory meetings and they try to facilitate transportation to Seattle. That's the closest academic center to them. Collaborating with telemedicine appointments, starting earlier, developing that strong relationship with patients, and contacting them between visits [can help patients living in rural areas]." TS 25:22 "I think the biggest [psychosocial challenge] I see is a lot of unmet anxiety and depression counseling. A lot of times, [patients are] losing their place in their family because they're the ones that need all the help now. Also, the uncertainty that goes along with the diagnosis. There is communication skills counseling, and End-of-Life Nursing Education Consortium (ELNEC) has a lot of training for communication skills and how to really talk to patients. Not that we take the place of a psychologist, but just being able to talk to somebody can go a long way. And if we can get training for that, we can help more patients." TS 31:15

Want a suitcase of antibiotics? Online “wellness” companies will oblige, but the disruption to your microbiome may last up to 8 years; What's the best form of curcumin? New push to promote nutrition instruction for doctors—is it enough? “Borderline anemia”—what could be the cause?

"We want to make sure that we discuss the details of the treatment and what treatments there are, whether it's an oral drug, whether it's a subcutaneous injection or an IV injection, [the patient's] potential for responding, whether this treatment is curative or supportive, and what the number of visits are. All of those different pieces of information that go into the decision-making process are really important," ONS member Sara Tinsley-Vance, PhD, APRN, AOCN®, nurse practitioner and quality-of-life researcher at Moffitt Cancer Center in Tampa, FL, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about myelodysplastic syndrome (MDS) treatment considerations. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 15, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge about the treatment considerations for MDS. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 411: An Overview of Myelodysplastic Syndrome for Oncology Nurses Episode 256: Cancer Symptom Management Basics: Hematologic Complications ONS Voice articles: FDA Approves Luspatercept-Aamt for Anemia in Adults With MDS Infection Prevention for Oncology Nurses Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents Whole-Genome Sequencing May Guide Treatment Choices for AML and MDS Clinical Journal of Oncology Nursing articles:  Reducing Effects of Hospital-Associated Deconditioning in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Resilience in Older Adults Diagnosed With Cancer and Receiving Chemotherapy Targeted Drug Therapies: Beyond Blood Counts and Chemistries Oncology Nursing Forum article: Frailty in Patients With Hematologic Malignancies and Those Undergoing Transplantation: A Scoping Review ONS books:  BMTCN™ Certification Review Manual (second edition) Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) ONS course: Hematopoietic Stem Cell Transplantation™ ONS Learning Library: Hematology, Cellular Therapy, and Stem Cell Transplantation ONS Symptom Intervention resources: Prevention of Infection: General Prevention of Infection: Transplant Aplastic Anemia and MDS International Foundation: MDS Drugs and Treatments Blood Cancer United: MDS Treatment HealthTree Foundation Myelodysplastic Syndromes Foundation To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The goals that I try to consolidate to make sure they're consistent with the patient's goals are to improve their counts, especially the anemia or cytopenias. If they're getting blood transfusions, we want to reduce the number of transfusions that they receive because we know that's linked to reduced overall survival, and it really impacts quality of life. ... And then for high-risk patients, it's a more serious discussion because we know that they are the ones who can progress to acute myeloid leukemia (AML). And we're trying to delay progression to AML. That means we're trying to improve their survival and we're also trying to manage their cytopenias and decrease their infection risk." TS 2:28 "If we look at approvals for low-risk disease and high-risk disease, those were really made based on the Revised International Prognostic Scoring System (IPSS-R) and sometimes the International Prognostic Scoring System (IPSS). Under those classification systems, when we think of lower-risk MDS, we think of patients who are primarily anemic but don't have increased blasts in their bone marrow. ... For higher-risk MDS, we want to have that discussion with those patients because their life expectancy is much shorter than patients with lower-risk MDS. We want to see if hematopoietic stem cell transplant would be something that they would be interested in if they don't have a lot of comorbidities and are relatively healthy." TS 11:41 "There are a lot of things to consider—[patients'] blood counts, comorbidities, whether they're frail, and what their goals are. There are some patients where there's no way they would want to go through transplant. And some patients want to be cured, so it just depends on your patient." TS 14:22 "I think of hematopoietic allogeneic transplants as a treatment for more of the patients with higher-risk MDS. ... With the Molecular International Prognostic Scoring System (IPSS-M), a patient can have pretty good blood counts and not have increased blasts in the bone marrow. You could send them for a transplant referral upfront without having to give them additional treatment. ... There is a recent publication that said if a patient doesn't have more than 10% blast, you could refer to transplant as a first option. ... Also, if you had a lower-risk patient who is relatively young and doesn't have any other treatment options, this would also be a patient that you could refer to transplant to see if we could care for them, and then they wouldn't have to be getting transfused all the time." TS 21:12 "I think that we often think low-risk, no treatment needed, but it depends on the person. They often need ongoing supportive care to manage their symptoms even if they're not getting treatment. And just because we're not treating them, active observation, bringing them in to see how they're doing, if they've had infections, if their blood counts are changing, that is paying attention to them and doing something. Just because they're low-risk doesn't mean they don't need anything and we can just schedule for a one-year follow-up." TS 26:30

Listen to Barry describe the diagnosis, watch-and-wait, treatment, and survivorship for MDS, or Myelodysplastic Syndromes

"Not every patient with myelodysplastic syndrome (MDS) is going to progress and die. Only 10%–20% of them will evolve into acute myeloid leukemia. And not all of them need blood transfusions. Some present with low platelet count. It's not just people who are anemic that have MDS—it's different depending on what type of MDS they have. These are averages. We're giving you statistics based on averages, and you're an individual, so we want to treat you as an individual," ONS member Sara Tinsley-Vance, PhD, APRN, AOCN®, nurse practitioner and quality-of-life researcher at Moffitt Cancer Center in Tampa, FL, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about myelodysplastic syndrome. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 17, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Nurses caring for people with myelodysplastic syndrome require knowledge of its pathophysiology, the presenting symptoms, and its diagnosis. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 339: A Lesson on Labs: How to Monitor and Educate Patients With Cancer Episode 302: Patient Navigation Eliminates Disparities in Cancer Care Episode 256: Cancer Symptom Management Basics: Hematologic Complications ONS Voice articles: Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents Whole-Genome Sequencing May Guide Treatment Choices for AML and MDS Clinical Journal of Oncology Nursing articles:  Deciphering TP53 Mosaic Variants on Germline Biomarker Testing: Implications for Oncology Nurses Myeloid Malignancies: Recognizing the Risk of Germline Predisposition and Supporting Patients and Families Oncology Nursing Forum article: Impact of a Hematologic Malignancy Diagnosis and Treatment on Patients and Their Family Caregivers ONS book: BMTCN™ Certification Review Manual (second edition) ONS Clinical Practice resource: Genomics Taxonomy Genomics and Precision Oncology Learning Library American Cancer Society: Myelodysplastic Syndrome Prognostic Scores Aplastic Anemia and MDS International Foundation Blood Cancer United: MDS Diagnosis HealthTree Foundation Myelodysplastic Syndromes Foundation: What Is MDS? To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "In the bone marrow maturation process, you have a pluripotent stem cell. You have myeloid and lymphoid, and then on the myeloid side, you make your white blood cells, your red blood cells, and your platelets. And during that maturation process, there's this problem that arises. It's called a clonal variation. Or something goes wrong as the cells go through that process year after year. It's called ineffective hematopoiesis. ... That process of becoming mature, functioning cells, arising from that hematopoietic stem cell is broken, and this leads to low blood counts. Usually, it's anemia, so the hemoglobin is low. You can see that the mean corpuscular volume (MCV) is really high, and those are clues that a patient might have MDS—anemia with a high MCV." TS 3:05 "The International Prognostic Scoring System (IPSS) was the first way that we staged MDS into lower-risk and higher-risk disease. Now we have the IPSS-R, which is the revised system. And that was intended to be a way of classifying patients into lower-risk or higher-risk disease, where we talked about the goals being different. And it's really looking at the depth of the cytopenias, so how low are those neutrophils? How low is the hemoglobin and the platelet level? What percentage of blast does the patient have in their bone marrow? [This] gauges whether they have lower-risk or higher-risk disease. And now that we have the Molecular International Prognostic Scoring System (IPSS-M), we also take into account the variants that a patient has and that can really change whether you think they have lower-risk or higher-risk disease." TS 8:46 "During a person's lifetime, if they were a heavy smoker, we always think of lung cancer, but it can actually predispose a person to MDS. If they worked heavily in chemicals. I can remember more than one patient who worked for pesticide companies. Repeated exposure to these things that can affect our blood cells cumulatively, they can make a person more prone to MDS. Also, patients who have family members who have had bone marrow problems." TS 13:39 "The way I explain it to patients who say, 'What does dysplasia mean?' I say, 'Well, if you had a picture of a face. If the cell has too many eyes, or one eye above the other or below the other, or too many ears, or they're just disfigured. They don't look right and they don't mature normally.' And so, the descriptions I frequently see are nuclear budding and micromegakaryocytes. Once you read a lot of the reports, you start to pick out, 'Okay, these are the terms that go along with dysplastic red blood cells or dysplastic megakaryocytes,' which are your precursors to platelets." TS 21:28 "The cytogenetics and the variants—that's a hard concept to explain to patients. And staying current on how we understand the disease and how it evolves. Now we have pre-MDS states called clonal cytopenia of undetermined significance. That was new to me. And then clonal hematopoiesis of indeterminate significance. And some of those clones have other healthcare problems that go along with them." TS 30:52

After exercise, does it matter whether you take a protein supplement—or just eat a protein-rich meal? Can melatonin alleviate Irritable Bowel Syndrome? Solutions for Myelodysplastic Syndrome—do you have to stop all supplements? The pros and cons of afternoon naps; Water softening may hike cardio risk; Anthocyanins from foods or supplements can improve impaired glucose tolerance.

Mikkael A. Sekeres, MD, MS Curious about what's new in the world of myelodysplastic syndromes (MDS)? We're bringing you the latest insights straight from one of the field's leading experts. In this episode, we speak with Dr. Mikkael Sekeres, of the Sylvester Comprehensive Cancer Center at University of Miami Health. Recorded onsite at the 2025 ASH (American Society of Hematology) Annual Meeting and Exposition, this conversation explores what MDS is, how it's treated today, and what researchers are learning about managing side effects. Dr. Sekeres also walks us through the most notable MDS updates presented at ASH, highlighting promising therapies and clinical trial data that may help shape future care. Whether you're newly learning about MDS or following ongoing research, this episode offers an accessible look at where things stand and what's on the horizon. *This is not an official program of the ASH annual meeting DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Myelodysplastic syndromes International Prognostic Scoring System for MDS American Society of Hematology Highlights from ASH vlog Blood cancer research 2026: Meeting patients where they want to be | blog post Additional Blood Cancer United Support Resources: Free Nutrition Consultations Information Specialists Financial support Clinical Trial Support Center Online Chat Free telephone/web patient programs Free booklets Young Adult Resources Support groups Caregiver support Caregiver Workbook Survivorship Workbook Advocacy and Public Policy Patient Community Mental Health Resources Episode supported by Geron Corporation and Taiho Oncology, Inc.The post The Bloodline Live! Myelodysplastic Syndromes (MDS) Updates in Research first appeared on The Bloodline with Blood Cancer United Podcast.

Oprah's new book encourages followers to “free themselves” from “shame and blame” by accessing weight loss meds; Her claim “it's the obesity gene” is put to the test by twin studies; Study shows brain stimulation with external electronic headset produces weight loss rivaling shots, pills; Ultra-processed food ups daily calorie intake by 500; Breast-feeding moms gain less post-pregnancy weight; Solutions for  Myelodysplastic Syndrome; Scientists find hidden weight gain trigger in soybean oil.

Please visit answersincme.com/860/99519635-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Guillermo Garcia-Manero, MD and John Mascarenhas, MD. In this activity, experts in Myelodysplastic Syndromes discuss the latest data for the treatment of anemia in patients with MDS and myelofibrosis. Upon completion of this activity, participants should be better able to: Discuss the latest data for the treatment of anemia in patients with myelodysplastic syndromes (MDS) and myelofibrosis (MF); and Translate the latest data into real-world treatment plans for the treatment of anemia.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/GKY865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.MASTER MDS for Enhanced Patient Care: Modern Advances With Standard and Emerging Risk-Adapted Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Ascentage Pharma, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/GKY865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.MASTER MDS for Enhanced Patient Care: Modern Advances With Standard and Emerging Risk-Adapted Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Ascentage Pharma, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/GKY865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.MASTER MDS for Enhanced Patient Care: Modern Advances With Standard and Emerging Risk-Adapted Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Ascentage Pharma, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/GKY865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.MASTER MDS for Enhanced Patient Care: Modern Advances With Standard and Emerging Risk-Adapted Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Ascentage Pharma, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/GKY865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.MASTER MDS for Enhanced Patient Care: Modern Advances With Standard and Emerging Risk-Adapted Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Ascentage Pharma, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/GKY865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.MASTER MDS for Enhanced Patient Care: Modern Advances With Standard and Emerging Risk-Adapted Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Ascentage Pharma, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

In this podcast episode, Rami Komrokji, MD, reviews data from select presentations in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) presented at the ASH 2025 Annual Meeting and shares expert perspectives on the clinical implications of these findings, including:Abstract 910: MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive MFAbstract 1024: Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential ThrombocythemiaAbstract 484: Preliminary Results From 2 Phase I Trials Exploring the Mutant Calreticulin-Specific mAb INCA033989 ± Ruxolitinib in Patients With MFAbstract 235: VERONA: Subgroup Analyses of Venetoclax or Placebo Combined With Azacitidine in Treatment-Naive Higher-Risk MDSAbstract 490: IMerge Post Hoc Analysis: Treatment-Emergent Cytopenias and Response With Imetelstat in Patients With Lower-Risk MDSAbstract 487: Randomized Phase II Trial of Reduced Treatment Durations of Hypomethylating Agents for Lower-Risk MDSPresenter: Rami Komrokji, MDSenior Member, Vice ChairSection Head – Leukemia and MDSDepartment of Malignant HematologyH. Lee Moffitt Cancer CenterProfessor of Oncologic SciencesUniversity of South FloridaTampa, FloridaContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program: https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

- Discussion of Myelodysplastic Syndromes (MDS) - Diagnosis, Staging & Current Standard of Care - The Role of Hematopathology Examination of a Sample of Your Bone Marrow in Making a Definitive Diagnosis of MDS - New & Emerging Treatment Approaches - The Role of Clinical Trials: How Research Increases Your Treatment Options - Tips to Manage Symptoms, Treatment Side Effects, Discomfort, Pain & Quality-of-Life Concerns - Nutrition & Hydration Concerns & Tips - Key Questions to Ask Your Health Care Team During Telehealth Appointments - Guidelines to Prepare for Telehealth Appointments Including Technology, Prepared List of Questions & Discussion of OpenNotes - Next Steps After Treatment, Including Follow-up Care in Collaboration with Your Primary Care Doctor & Team - Questions for Our Panel of Experts

00:00:00 - Intro 00:00:53 - Stage 4 Colon Cancer 00:31:14 - Myelodysplastic syndrome (MDS) 00:39:48 - Eye Issues - Shingles (Herpes Zoster) - Macular Edema - ERM (Epiretinal Membrane) 00:49:59 - TMJ (Temporomandibular Joint) -  Skin Issue - Stye - Neuralgia 00:58:29 - Female Reproductive Tonic 01:03:56 - Chronic Fatigue - Brain Fog - Overwhelmed - Toenail Fungus - Athlete's Foot 00:00:53 - Stage 4 Colon Cancer About 18 months later, the cancer returned—this time involving her ovaries, uterus, liver and peritoneal cavity. 00:31:14 - Myelodysplastic syndrome (MDS) It is a type that could potentially develop into acute leukemia in the future. 00:39:48 - Eye Issues - Shingles (Herpes Zoster) - Macular Edema - ERM (Epiretinal Membrane) I refused the last injection because I feel there has to be an alternative to this. 00:49:59 - TMJ (Temporomandibular Joint) -  Skin Issue - Stye - Neuralgia I have near constant pain/irritation on left side of my scalp.  00:58:29 - Female Reproductive Tonic Is there an issue with a woman in menopause, age 70, taking the Female Reproductive Tonic? 01:03:56 - Chronic Fatigue - Brain Fog - Overwhelmed - Toenail Fungus - Athlete's Foot I have healed fibromyalgia, suicidal thoughts, depression and autistic tendencies.

Broadcast icon and breast cancer survivor Robin Roberts joins Sarah for an intimate conversation about the strength it takes to show up — especially when the cameras are off. Robin reflects on her groundbreaking career in sports journalism and morning television, the decision to go public with her diagnoses, and how surviving cancer and MDS – Myelodysplastic Syndrome – reshaped her sense of purpose. Robin and Sarah explore what it means to lead with grace, advocate for others, and live a life of visibility both behind the news desk and far beyond it. Follow Robin on Instagram here Leave us a voicemail at 872-204-5070 or send us a note at goodgame@wondermedianetwork.com Follow Sarah on social! Bluesky: @sarahspain.com Instagram: @Spain2323 Follow producer Misha Jones! Bluesky: @mishthejrnalist.bsky.social Instagram: @mishthejrnalist Follow producer Alex Azzi! Bluesky: @byalexazzi.bsky.social See omnystudio.com/listener for privacy information.

VJHemOnc recently attended the 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025, held in Lisbon,... The post iwMDS wrap-up: translating research into practice to optimize patient care appeared first on VJHemOnc.

In this episode of Hema Now, host Jonathan Sackier is joined by Kevin Rouault-Pierre and Onima Chowdhury, to explore the biological mechanisms behind MDS, with a spotlight on SF3B1 mutations. From epigenetic stress to diagnostic strategies, this discussion bridges laboratory research and frontline care.  Timestamps 01:11 – Quickfire Round 07:11 – Haematology Misconceptions  10:56 – Understanding MDS 18:42 – Treating Myeloid Malignancies 23:20 – Epigenetic Mechanisms 28:30 – MDS Treatment Approaches 34:56 – Three Wishes 

In this week's episode we'll learn more about a novel mouse model that recapitulates many of the properties of human sickle cell SC disease; results from the induction phase of the risk-adapted MIDAS trial of isatuximab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma; and a link between splicing factor mutations and competitive fitness in myelodysplastic syndrome stem cells.Featured articles:A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyureaIsatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trialCell-autonomous dysregulation of interferon signaling drives clonal expansion of SRSF2-mutant MDS stem/progenitor cells

- Discussion of Myelodysplastic Syndrome (MDS), in the Context of Infectious Diseases - Diagnosis, Staging & Current Standard of Care - The Role of Hematopathology Examination of a Sample of Your Bone Marrow in Making a Definitive Diagnosis of MDS - New & Emerging Treatment Approaches - The Role of Clinical Trials: How Research Increases Your Treatment Options - Tips to Manage Symptoms, Treatment Side Effects, Discomfort, Pain & Quality-of-Life Concerns - Nutrition & Hydration Concerns & Tips - Key Questions to Ask Your Health Care Team During Telehealth Appointments - Guidelines to Prepare for Telehealth Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Next Step After Treatment, Including Follow-Up Care in Collaboration with Your Primary Care Doctor & Team - Questions for Our Panel of Experts

To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.

In this week's episode we'll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic syndromes, the immune checkpoint regulator VISTA as a potential target for preventing graft-vs-host disease, and epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma.Featured Articles:IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromesTargeting cell-surface VISTA expression on allospecific naïve T cells promotes toleranceEpcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

In this week's episode we'll learn more about azacitidine-venetoclax combination therapy for first-line treatment of high-risk myelodysplastic syndromes; a new risk-scoring system for post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia, also known as B-ALL; and a novel mechanism for inotuzumab ozogamicin resistance in B-ALL.Featured Articles:Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromesDevelopment of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemiaDNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia

This week, Jonathan is joined by Eytan Stein, Chief of the Leukaemia Service and an Attending Physician at Memorial Sloan Kettering Cancer Center, New York, USA.  Timestamps:      (00:00)-Introduction  (01:05)-The current landscape of treatments  (02:26)-The promise and peril of differentiation therapy  (05:55)-Highlighting the most impactful clinical trials  (08:38)-Epigenetics and the future of targeted therapies  (10:40)-The BEAT AML master clinical trial  (12:57)-The latest research into IDH inhibitors  (16:10)-Therapies for splicing factor mutations  (19:29)-Reducing patient fear with education   (22:46)-Stein's three wishes for healthcare   

Research continues to accelerate for myelodysplastic syndromes (MDS), giving hope to patients and their loved ones. In this episode, Dr.… The post There's Always Hope: Myelodysplastic Syndromes (MDS) first appeared on The Bloodline with LLS.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/XNT865. CME/MOC/AAPA credit will be available until January 5, 2026.Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelodysplastic Syndromes. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.Disclosure information is available at the beginning of the video presentation.

This week, Jonathan is joined by Dr Shahram Kordasti, Associate Professor in Applied Cancer Immunopathology at King's College London, UK. In this episode, Dr Kordasti discusses the immunobiology of Myelodysplastic syndrome and Aplastic anaemia, the role of CD4+ T cells in myeloid malignancies, and how cutting-edge computational tools are enhancing treatment strategies.   Timestamps:  (00:00)-Introduction  (01:23)-Hodgkin's lymphoma origin   (04:21)- Immunobiology of diseases  (08:55)-Plasticity of T cells   (13:42)-Computational biology and multiomics for patient stratification  (21:00)-Standardising immune monitoring  (25:41)- Pretreatment with systemic agents  (27:55)- Myeloproliferative neoplasms  (31:48)-Synthetic data generation   (36:22)-Exciting developments on the horizon   (39:16)-Three wishes for healthcare  

Featuring perspectives from Dr Harry Paul Erba, moderated by Dr Stephen “Fred” Divers CME information and select publications

Dr Harry Paul Erba shares his perspectives on the evolving therapeutic landscape for patients with leukemia and myelodysplastic syndromes, moderated by Dr Stephen "Fred" Divers. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/AON24).

Dr Harry Paul Erba shares his perspectives on the evolving therapeutic landscape for patients with leukemia and myelodysplastic syndromes.

This week Jonathan is joined by Joshua Zeidner, Associate Professor of Medicine, University of North Carolina School of Medicine, USA. Together, they discuss findings from recent research and treatment options for acute myeloid leukaemia and myelodysplastic syndrome. Timestamps:     (00:00)- Introduction    (01:57)- Joshua's love for the New York Giants  (04:28)- Treatment outcomes in IDH1 and IDH2-mutated acute myeloid leukaemia (AML)  (08:05)- Safety and efficacy of new agents in AML  (17:00)- Treatments for patients with AML with a TP53 mutation  (22:02)- Reliance on transfusion in myelodysplastic syndrome (MDS)  (25:44)- The time from research lab to bedside in drugs to treat AML and MDS  (30:50)- Joshua's three wishes for healthcare   (35:13)- Outro   

In this week's episode, we'll learn about the role of a platelet-specific glycoprotein receptor in abdominal aortic aneurysm formation, the influence of TP53 mutations on outcomes for patients with 5q-deleted myelodysplastic syndrome, and a rational combination treatment intended to produce more durable responses in patients with refractory B-cell acute lymphoblastic leukemia who are treated with CAR T-cell therapy.Featured Articles:Soluble glycoprotein VI predicts abdominal aortic aneurysm growth rate and is a novel therapeutic targetInfluence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletionA phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Azra Raza, Professor of Medicine and Director of the Myelodysplastic Syndrome (MDS) Center at Columbia University in New York, joins Jonathan Sackier to discuss her mission to shift the field of oncology, ensuring it focuses on eliminating the first cancer cell rather than chasing after the last.     Timestamps:   (00:00)-Introduction  (02:37)-Poetry  (08:50)-Raza's journey into oncology  (14:41)-Myelodysplastic syndrome and Raza's tissue bank  (21:16)-The First Cell    (28:18)-The cancer Questions Project  (38:20)-Goals for the future  (44:40)-The most pressing issues in cancer care  (48:14)-Financially incentivising early detection  (57:00)-3 Quarks Daily  (59:10)-Three wishes for healthcare   

In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including:Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractory AML Phase I/II study of oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with newly diagnosed and relapsed/refractory FLT3-mutant AMLA retrospective comparison of abbreviated course 7+7 vs standard HMA plus venetoclax doublet in older/unfit patients with newly diagnosed AML Multisite randomized trial of a collaborative palliative and oncology care model for patients with AML and myelodysplastic syndromes (MDS) receiving nonintensive therapyFinal 5-year results from the phase II pivotal cohort of olutasidenib for IDH1-mutated AML Post hoc analyses of outcomes in patients with AML and MDS-related changes who received oral azacitidine maintenance therapy in the phase III QUAZAR AML-001 studyFirst-in-human phase I/II of the menin-MLL inhibitor DSP-5336 in patients with R/R acute leukemia: updated results from the dose escalation phase A phase Ib study of the menin-KMT2A inhibitor bleximenib in combination with venetoclax and azacitidine in R/R AML with alterations in KMT2A or NPM1 Program faculty:Eunice S. Wang, MDChief, Leukemia and Benign Hematology ServiceProfessor of OncologyRoswell Park Comprehensive Cancer CenterBuffalo, New YorkCourtney DiNardo, MD, MSCEProfessor of MedicineDepartment of LeukemiaMD Anderson Cancer CenterHouston, TexasResources:To download the slides associated with this podcast discussion, please visit the program page:https://bit.ly/4bvJGij

In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the  EHA 2024 Congress including:COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low–, low- or intermediate-risk MDSReal-world dose-escalation and outcomes among patients with lower-risk MDS receiving luspatercept in clinical practicePhase II ASTREON trial―preliminary safety/efficacy of oral azacitidine in low-/intermediate, intermediate-risk, MDSPhase III IMerge: overall survival and transfusion independence with imetelstat in patients with low-risk or intermediate-1–risk MDS Phase III ENHANCE study of magrolimab plus azacitidine vs azacitidine plus placebo for higher-risk MDS Oral decitabine/cedazuridine plus venetoclax vs oral decitabine/cedazuridine alone in high-risk MDS: a propensity score analysis Program faculty:Courtney DiNardo, MD, MSCEProfessor of MedicineDepartment of LeukemiaMD Anderson Cancer CenterHouston, TexasBrady L. Stein, MD, MHSProfessor of MedicineDepartment of Hematology/OncologyNorthwestern University Feinberg School of MedicineChicago, IllinoisEunice S. Wang, MDChief, Leukemia and Benign Hematology ServiceProfessor of OncologyRoswell Park Comprehensive Cancer CenterBuffalo, New YorkResources:To download the slides associated with this podcast discussion, please visit the program page.

Recorded LIVE! At Johns Hopkins Internal Medicine Grand Rounds Step up your anemia game as we explore the causes and diagnostic approach for macrocytic anemia, what to do with a reticulocyte count, the differential diagnosis for hemolytic anemia, the significance of the direct antiglobulin test, and diagnosis and management pearls for autoimmune hemolytic anemia (AIHA) and myelodysplastic syndrome (MDS). Plus, common questions and concerns regarding folate supplementation and the use of bone marrow biopsies. We're joined by hematologist and pun enthusiast Dr. Rakhi Naik MD, MHS, @redcell_doc @hopkinsheme.  Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Intro and Guest intro 05:53 Case 1: Elise - Macrocytic Anemia 14:59 Case 2: Jane - Hemolytic Anemia 23:24 Testing for Underlying Causes of Autoimmune Hemolytic Anemia 24:40 Association of Autoimmune Hemolytic Anemia with Lymphomas 25:10 Autoimmune Hemolytic Anemia: Diagnosis and Treatment 26:06 Management Approach for Autoimmune Hemolytic Anemia 27:30 Considerations for Outpatient Treatment of Autoimmune Hemolytic Anemia 28:18 Clotting Risk in Autoimmune Hemolytic Anemia 29:20 Treatment Options for Autoimmune Hemolytic Anemia 30:42 Long-Term Prognosis and Recurrence of Autoimmune Hemolytic Anemia 33:32 Diagnostic Challenges in Myelodysplastic Syndrome 35:00 Considerations for Folate Supplementation 36:24 Factors to Consider in the Management of Myelodysplastic Syndrome 39:30 When to Perform a Bone Marrow Biopsy in Myelodysplastic Syndrome 41:25 Shared Decision-Making in the Treatment of Myelodysplastic Syndrome Credits Writer and Producer: Matthew Watto MD, FACP Show Notes: Matthew Watto MD, FACP Cover Art and Infographic: Matthew Watto MD, FACP Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Fatima Syed MD, MSc Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Rakhi P. Naik MD, MHS Sponsor: Beginly Health Visit beginlyhealth.com/curbsiders job matching platform for every Physician and Advanced Practice Clinician, from training to practice. Sponsor: Freed You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month. Sponsor: Babbel Get up to 60% off your Babbel subscription, for a limited time, at Babbel.com/CURB. 

Featuring perspectives from Dr Richard M Stone, including the following topics:  • Introduction: ASH 2023 Update — Key Oral Presentations (0:00) • Case: A woman in her early 90s with dementia who presented with anemia and was diagnosed with low-risk myelodysplastic syndromes (MDS) with ring sideroblasts, now receiving luspatercept — Eric H Lee, MD, PhD (9:09) • Case: An African American woman in her early 60s with high-risk del(5q) MDS who receives oral decitabine/cedazuridine — Henna Malik, MD (26:05) • Case: A man in his late 60s with therapy-related acute myeloid leukemia (AML) with a FLT3-ITD mutation — Rebecca L Olin, MD, MSCE (34:49) • Case: A woman in her early 70s with PMH of inflammatory breast cancer diagnosed with FLT3-ITD AML who achieved a complete response (CR) with azacitidine/venetoclax, followed by gilteritinib maintenance for 2 years — Zanetta S Lamar, MD (40:43) • Case: A man in his mid 30s who presents with pathologic spinal fracture, is diagnosed with myeloid sarcoma and receives induction CLAG-M with CR followed by consolidation high-dose cytarabine — Anna Halpern, MD (43:56) • Case: A man in his mid 80s with MDS, complex cytogenetics and a TP53 mutation treated with azacitidine/venetoclax — Neil Morganstein, MD (46:40) • Case: A woman in her early 70s with newly diagnosed, poor-risk AML, ineligible for intensive chemotherapy (ECOG PS 2) who receives a hypomethylating agent/venetoclax — Amany R Keruakous, MD, MS (49:56) • Case: A man in his early 70s with relapsed AML (SRSF2, IDH1, ASXL1 mutations) after azacitidine/venetoclax, now receiving ivosidenib — Dr Halpern (55:23)   CME information and select publications  

Dr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes.

Dr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/MTPAMLMDS23/Part3).

Myelodysplastic Syndromes (MDS) is a group of diseases that have a variety of different treatments and outcomes. In this episode,… The post Improving Quality of Care for Myelodysplastic Syndromes (MDS) first appeared on The Bloodline with LLS.

Myelodysplastic Syndromes (MDS) is a group of diseases that have a variety of different treatments and outcomes. In this episode,… The post Improving Quality of Care for Myelodysplastic Syndromes (MDS) appeared first on The Bloodline with LLS.

In discussion with Dr. Amer Zeidan, covering how to treat myelodysplastic syndrome (MDS) in community settings. Dr. Zeidan is the director of early therapeutics research and associate professor of medicine at the Yale School of Medicine – Smilow Cancer Hospital. With Dr. Zeidan we covered MDS management in low-risk and high-risk patient population.   #PrecisionMedicine #Hematology #Cancer #Malignancy #MDS #BloodCancer #oncology #oncbrothers